drugset / Trial / NCT00751803
BI 44370 TA in Acute Migraine Attack
RandomizedParallel-groupTreatment
Summary
The objective of this trial is to assess the safety, tolerability, and efficacy of three doses of BI 44370 TA in the treatment of patients with an acute migraine attack and headache pain of moderate or severe intensity, compared to placebo and an active comparator.
Timeline
- Start
- 2008-08
- Primary completion
- 2009-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 44370 | Small molecule | 50 mg | Oral |
| Subject | BI 44370 | Small molecule | 200 mg | Oral |
| Subject | BI 44370 | Small molecule | 400 mg | Oral |
| Comparator | Eletriptan | Small molecule | — | — |